Please assess the completion status of the following clinical trial:

Trial Title: Gastrografin for Treating Small Bowel Obstruction in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed small bowel obstruction by a surgeon or physician~* Patient has undergo 24 hours of monitoring and non-surgical management (NG tube decompression, IV fluids, and NPO)~* Patients are between 6 month and 18 years of age at time of diagnosis~Exclusion Criteria:~* Abnormal levels of thyroid stimulating hormone (TSH) or thyroxine (T4)~* Prior thyroid surgery~* Receiving thyroid hormone replacement therapy~* Allergy to medical or non-medial ingredients in Gastrografin~* Weight of less than 10kg at time of diagnosis

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Gastrografin Arm (Type: EXPERIMENTAL): Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
- Control Arm (Type: EXPERIMENTAL): Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.

Based on this trial design, predict the completion outcome and termination type (if applicable).